Viennese cancer-immunotherapy focused group Apeiron Biologics has appointed a new chief financial officer and chief business officer in the form of Peter Llewellyn-Davies.
With more than 25 years’ experience in initial public offerings, mergers and acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, Llewellyn-Davies most recently ran his own consulting firm Accellerate Partners.
He said: “Apeiron is currently amongst the most compelling privately owned European biotech companies and I am looking forward to working together with the team to jointly lead Apeiron through the next phase of growth.”
During the course of his career, Llewellyn-Davies supported Medigene’s strategy to form an immunotherapy company and he assisted in initial public offerings for Wilex.
Dr Hans Loibner, chief executive officer, Apeiron, said: “Peter’s expertise, which has been proven by many international capital market transactions, is highly welcome, and he is an ideal addition to support our growth strategy.
“I very much look forward to working hand in hand with him.”